By co‐delivering tumor‐specific neoantigens and a cholesterol‐coupled toll‐like receptor 9 (TLR9) agonist within LNP‐vaxD18, an approximately 60‐fold increase in dendritic cell uptake compared to neoantigen‐adjuvant mixtures is achieved. Here, TLR9 is linked to neoplasm.